サマリー

心臓安全性サービス市場は、2022年の6億米ドルから2027年には10億米ドルに達すると予測され、予測期間中のCAGRは11.2%となります。製薬会社による支出の増加と政府支出の増加により、この業界では新薬開発のための研究開発活動のペースが加速しています。このため、心臓の安全性評価など、医薬品開発における多くの前臨床および臨床サービスの必要性が高まっています。
"2021年のサービス種類別市場において、血圧測定分野が2番目に大きなシェアを占めている"
血圧測定は、心臓安全性評価サービスにおいて不可欠な要素です。研究開発活動の増加と厳しい臨床試験規制により、血圧測定は有効性と安全性の両方のエンドポイントから重要なパラメータとなっています。この要因は、この市場セグメントの成長を促進することが期待されます。
"2021年のエンドユーザー市場において、受託研究機関（CRO）が第2位のシェアを占めている"
CROは、製薬＆バイオ医薬品企業に対して、専門的なサービスを低コストで提供しています。その結果、多くの製薬＆バイオ医薬品企業が創薬サービスをCROにアウトソーシングしている。心臓安全性サービスは医薬品開発プロセスにおいて重要であるため、アウトソーシングの増加に伴い、その採用が進むと予想される。
米国Laboratory Corporation of America Holdings（米国）、Koninklijke Philips N.V.（オランダ）、Clario（米国）、Banook Group（フランス）、IQVIA（米国）、Biotrial（フランス）、Certara（米国）、Celerion（米国）、Medpace（米国）、Ncardia（オランダ）、Richmond Pharmacology（英国）、PhysioStim（フランス）、上海Medicilon（中国）、Pharmaceutical Product Development（米国）およびSGS（スイス）などの主要プレイヤーが市場に進出しています。

"ヨーロッパ心臓安全性サービス市場において2番目に大きなシェア"
欧州市場は、ドイツ、イギリス、フランス、イタリア、スペイン、RoEを含みます。心臓安全性サービス市場で2番目に大きな市場シェアを占めています。重要な考慮点は、慢性疾患の発生率の増加などの人口動態の変化が、同地域の市場成長を促進すると予想されることです。

本レポートのために実施した一次インタビューは、以下のように分類されます。

- 回答者別供給側：80％、需要側：20
- 役職別マネージャー - 45%、CXOとディレクターレベル - 30%、エグゼクティブ - 25
- 地域別北米：20％、欧州：10％、アジア太平洋：55％、RoW：15
報告書に掲載された企業一覧
- ラボラトリー・コーポレーション・オブ・アメリカ・ホールディングス (米国)
- フィリップス (オランダ)
- クラリオ（米国）
- バヌークグループ（フランス）
- IQVIA（米国）
- ビオトライアル（フランス）
- Certara（米国）
- Celerion社（米国）
- Medpace（米国）
- Ncardia（オランダ）
- リッチモンド・ファーマコロジー（英国）
- フィジオスティム（フランス）
- 上海メディシロン社（中国）
- ファーマシューティカル・プロダクト・デベロプメント（米国）
- SGS (スイス)
調査対象
本レポートは、心臓安全性サービス市場の詳細なイメージを提供します。タイプ、サービスタイプ、エンドユーザー、地域などの異なるセグメントにおける市場規模や今後の成長性を推定することを目的としています。また、主要な市場プレイヤーの企業プロファイルや最近の開発状況、主要な市場戦略とともに、詳細な競合分析も掲載しています。

レポート購入の主なメリット
本レポートは、心臓安全性サービス市場全体とそのサブセグメントに関する収益数の最も近い概算を提供することで、市場リーダー/新規参入者を支援するものです。また、利害関係者が競争状況をより良く理解し、自社のビジネスをより良く位置づけ、適切な市場参入戦略を立てるためのより多くの洞察を得るのに役立ちます。本レポートは、利害関係者が市場の鼓動を理解し、主要な市場促進要因、課題、動向、機会に関する情報を提供することを可能にします。

ページTOPに戻る

目次

1 INTRODUCTION 20
1.1 STUDY OBJECTIVES 20
1.2 MARKET DEFINITION 20
1.3 STUDY SCOPE 21
FIGURE 1 CARDIAC SAFETY SERVICES MARKET 21
1.4 YEARS CONSIDERED 21
1.5 CURRENCY CONSIDERED 22
1.6 LIMITATIONS 22
1.7 STAKEHOLDERS 22
2 RESEARCH METHODOLOGY 23
2.1 RESEARCH DATA 23
FIGURE 2 RESEARCH DESIGN 23
2.1.1 SECONDARY DATA 23
2.1.1.1 Key data from secondary sources 24
2.1.2 PRIMARY DATA 25
2.1.2.1 Key data from primary sources 25
2.1.2.2 Key industry insights 26
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 26
2.2 MARKET SIZE ESTIMATION 27
2.2.1 BOTTOM-UP APPROACH 27
FIGURE 4 BOTTOM-UP APPROACH 27
2.2.2 TOP-DOWN APPROACH 28
FIGURE 5 TOP-DOWN APPROACH 28
2.2.3 GROWTH FORECAST 28
2.3 DATA TRIANGULATION 29
FIGURE 6 DATA TRIANGULATION METHODOLOGY 29
2.4 RESEARCH ASSUMPTIONS 30
3 EXECUTIVE SUMMARY 31
FIGURE 7 CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2022 VS. 2027 (USD MILLION) 31
FIGURE 8 CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION) 32
FIGURE 9 CARDIAC SAFETY SERVICES MARKET, BY END USER, 2022 VS. 2027 (USD MILLION) 32
FIGURE 10 GEOGRAPHICAL SNAPSHOT OF CARDIAC SAFETY SERVICES MARKET 33
4 PREMIUM INSIGHTS 34
4.1 CARDIAC SAFETY SERVICES MARKET OVERVIEW 34
FIGURE 11 INCREASING NUMBER OF CLINICAL TRIALS TO DRIVE MARKET GROWTH 34
4.2 NORTH AMERICA: CARDIAC SAFETY SERVICES MARKET SHARE, BY TYPE AND COUNTRY (2021) 35
FIGURE 12 INTEGRATED SERVICES ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2021 35
4.3 CARDIAC SAFETY SERVICES MARKET SHARE, BY TYPE OF SERVICE, 2022 VS. 2027 36
FIGURE 13 ECG/HOLTER MEASUREMENT SERVICES SEGMENT TO DOMINATE MARKET IN 2027 36
4.4 CARDIAC SAFETY SERVICES MARKET SHARE, BY END USER, 2022 36
FIGURE 14 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE IN 2022 36
4.5 CARDIAC SAFETY SERVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 37
FIGURE 15 EUROPEAN COUNTRIES TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD 37
5 MARKET OVERVIEW 38
5.1 INTRODUCTION 38
5.2 MARKET DYNAMICS 38
FIGURE 16 CARDIAC SAFETY SERVICES MARKET: DRIVERS, OPPORTUNITIES, AND CHALLENGES 38
5.2.1 DRIVERS 39
5.2.1.1 Growing R&D expenditure in pharmaceutical & biopharmaceutical industry 39
FIGURE 17 GLOBAL PHARMACEUTICAL R&D SPENDING, 2012–2026 39
5.2.1.2 Increased outsourcing of R&D activities 39
FIGURE 18 ACTIVE PHARMACEUTICAL DRUG PIPELINE, JANUARY 2011 TO JANUARY 2021 40
5.2.1.3 Increasing number of clinical trials 40
FIGURE 19 INCREASING NUMBER OF CLINICAL TRIALS REGISTERED WORLDWIDE (2000–2021) 41
5.2.2 OPPORTUNITIES 41
5.2.2.1 Introduction of new technologies and methods 41
5.2.2.2 Growth in biosimilars and biologics markets 42
5.2.3 CHALLENGES 42
5.2.3.1 High cost of cardiac safety evaluation 42
6 CARDIAC SAFETY SERVICES MARKET, BY TYPE 43
6.1 INTRODUCTION 44
TABLE 1 CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 44
6.2 INTEGRATED SERVICES 44
6.2.1 INTEGRATED SERVICES TO DOMINATE CARDIAC SAFETY SERVICES MARKET 44
TABLE 2 INTEGRATED CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION) 44
TABLE 3 NORTH AMERICA: INTEGRATED CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 45
TABLE 4 EUROPE: INTEGRATED CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 45
TABLE 5 ASIA PACIFIC: INTEGRATED CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 46
6.3 STANDALONE SERVICES 46
6.3.1 STANDALONE SERVICES SEGMENT WITNESSING GROWTH DUE TO COST-EFFECTIVENESS 46
TABLE 6 STANDALONE CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION) 46
TABLE 7 NORTH AMERICA: STANDALONE CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 47
TABLE 8 EUROPE: STANDALONE CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 47
TABLE 9 ASIA PACIFIC: STANDALONE CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 48
7 CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE 49
7.1 INTRODUCTION 50
TABLE 10 CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020–2027 (USD MILLION) 50
7.2 ECG/HOLTER MEASUREMENT SERVICES 50
7.2.1 ECG/HOLTER MEASUREMENT SERVICES SUPPORT R&D IN NOVEL METHODS FOR CLINICAL TRIALS AND DRUG DISCOVERY 50
TABLE 11 ECG/HOLTER MEASUREMENT SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION) 51
TABLE 12 NORTH AMERICA: ECG/HOLTER MEASUREMENT SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 51
TABLE 13 EUROPE: ECG/HOLTER MEASUREMENT SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 51
TABLE 14 ASIA PACIFIC: ECG/HOLTER MEASUREMENT SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 52
7.3 BLOOD PRESSURE MEASUREMENT SERVICES 52
7.3.1 INCREASING R&D ACTIVITIES TO DRIVE MARKET GROWTH 52
TABLE 15 BLOOD PRESSURE MEASUREMENT SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION) 52
TABLE 16 NORTH AMERICA: BLOOD PRESSURE MEASUREMENT SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 53
TABLE 17 EUROPE: BLOOD PRESSURE MEASUREMENT SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 53
TABLE 18 ASIA PACIFIC: BLOOD PRESSURE MEASUREMENT SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 53
7.4 CARDIOVASCULAR IMAGING SERVICES 54
7.4.1 CARDIOVASCULAR IMAGING SERVICES HELP IN DRUG EVALUATION 54
TABLE 19 CARDIOVASCULAR IMAGING SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION) 54
TABLE 20 NORTH AMERICA: CARDIOVASCULAR IMAGING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 54
TABLE 21 EUROPE: CARDIOVASCULAR IMAGING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 55
TABLE 22 ASIA PACIFIC: CARDIOVASCULAR IMAGING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 55
7.5 THOROUGH QT STUDIES 55
7.5.1 NEED TO MEET STRINGENT REGULATORY REQUIREMENTS TO DRIVE DEMAND FOR THOROUGH QT STUDIES 55
TABLE 23 THOROUGH QT STUDIES MARKET, BY REGION, 2020–2027 (USD MILLION) 56
TABLE 24 NORTH AMERICA: THOROUGH QT STUDIES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 56
TABLE 25 EUROPE: THOROUGH QT STUDIES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 57
TABLE 26 ASIA PACIFIC: THOROUGH QT STUDIES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 57
7.6 OTHER SERVICES 58
TABLE 27 OTHER CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION) 58
TABLE 28 NORTH AMERICA: OTHER CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 58
TABLE 29 EUROPE: OTHER CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 59
TABLE 30 ASIA PACIFIC: OTHER CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 59
8 CARDIAC SAFETY SERVICES MARKET, BY END USER 60
8.1 INTRODUCTION 61
TABLE 31 CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION) 61
8.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES 61
8.2.1 INCREASING R&D BY PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES TO DRIVE DEMAND FOR CARDIAC SAFETY SERVICES 61
TABLE 32 CARDIAC SAFETY SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2020–2027 (USD MILLION) 62
TABLE 33 NORTH AMERICA: CARDIAC SAFETY SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION) 62
TABLE 34 EUROPE: CARDIAC SAFETY SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION) 62
TABLE 35 ASIA PACIFIC: CARDIAC SAFETY SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION) 63
8.3 CONTRACT RESEARCH ORGANIZATIONS 63
8.3.1 INCREASING OUTSOURCING OF DRUG DISCOVERY PROCESSES TO SUPPORT SEGMENT GROWTH 63
TABLE 36 CARDIAC SAFETY SERVICES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2020–2027 (USD MILLION) 63
TABLE 37 NORTH AMERICA: CARDIAC SAFETY SERVICES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 64
TABLE 38 EUROPE: CARDIAC SAFETY SERVICES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 64
TABLE 39 ASIA PACIFIC: CARDIAC SAFETY SERVICES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 65
9 CARDIAC SAFETY SERVICES MARKET, BY REGION 66
9.1 INTRODUCTION 67
TABLE 40 CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION) 67
9.2 NORTH AMERICA 67
FIGURE 20 NORTH AMERICA: CARDIAC SAFETY SERVICES MARKET SNAPSHOT 68
TABLE 41 NORTH AMERICA: CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 69
TABLE 42 NORTH AMERICA: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020–2027 (USD MILLION) 69
TABLE 43 NORTH AMERICA: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 69
TABLE 44 NORTH AMERICA: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION) 70
9.2.1 US 70
9.2.1.1 US dominates global cardiac safety services market 70
TABLE 45 US: TOTAL NUMBER OF CLINICAL TRIALS (2019) 70
TABLE 46 US: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020–2027 (USD MILLION) 71
TABLE 47 US: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 71
TABLE 48 US: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION) 71
9.2.2 CANADA 72
9.2.2.1 Canada has high-quality clinical trial infrastructure and expertise 72
TABLE 49 CANADA: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020–2027 (USD MILLION) 72
TABLE 50 CANADA: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 73
TABLE 51 CANADA: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION) 73
9.3 EUROPE 73
FIGURE 21 EUROPE: CARDIAC SAFETY SERVICES MARKET SNAPSHOT 74
TABLE 52 EUROPE: CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 75
TABLE 53 EUROPE: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020–2027 (USD MILLION) 75
TABLE 54 EUROPE: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 75
TABLE 55 EUROPE: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION) 76
9.3.1 GERMANY 76
9.3.1.1 Availability of skilled staff and flexible labor laws have made Germany a popular EU hub for clinical trials 76
TABLE 56 GERMANY: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020–2027 (USD MILLION) 77
TABLE 57 GERMANY: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 77
TABLE 58 GERMANY: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION) 77
9.3.2 UK 78
9.3.2.1 Steady growth of pharmaceutical R&D expenditure indicates favorable prospects for cardiac safety services 78
TABLE 59 UK: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020–2027 (USD MILLION) 78
TABLE 60 UK: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 79
TABLE 61 UK: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION) 79
9.3.3 FRANCE 79
9.3.3.1 High clinical trial activity for cancer therapies to drive market growth 79
TABLE 62 FRANCE: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020–2027 (USD MILLION) 80
TABLE 63 FRANCE: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 80
TABLE 64 FRANCE: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION) 80
9.3.4 ITALY 81
9.3.4.1 Strong pharma industry and availability of funding for drug development fuel market growth 81
TABLE 65 NUMBER OF CLINICAL TRIALS STARTED IN ITALY, BY COMPANY (JANUARY 2021) 81
TABLE 66 ITALY: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020–2027 (USD MILLION) 82
TABLE 67 ITALY: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 82
TABLE 68 ITALY: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION) 82
9.3.5 SPAIN 83
9.3.5.1 Growing investment in pharmaceutical R&D and a favorable climate for approvals boost market growth 83
TABLE 69 SPAIN: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020–2027 (USD MILLION) 83
TABLE 70 SPAIN: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 84
TABLE 71 SPAIN: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION) 84
9.3.6 REST OF EUROPE 84
TABLE 72 ROE: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020–2027 (USD MILLION) 85
TABLE 73 ROE: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 85
TABLE 74 ROE: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION) 86
9.4 ASIA PACIFIC 86
TABLE 75 APAC: CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 87
TABLE 76 APAC: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020–2027 (USD MILLION) 87
TABLE 77 APAC: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 87
TABLE 78 APAC: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION) 88
9.4.1 CHINA 88
9.4.1.1 China dominates APAC market for cardiac safety services 88
TABLE 79 CHINA: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020–2027 (USD MILLION) 88
TABLE 80 CHINA: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 89
TABLE 81 CHINA: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION) 89
9.4.2 JAPAN 89
9.4.2.1 Strong IP rights and supportive policies have strengthened R&D sector in Japan 89
TABLE 82 JAPAN: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020–2027 (USD MILLION) 90
TABLE 83 JAPAN: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 90
TABLE 84 JAPAN: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION) 90
9.4.3 INDIA 91
9.4.3.1 Lack of language barriers and availability of trained resources make India an attractive destination for clinical trials 91
TABLE 85 INDIA: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020–2027 (USD MILLION) 91
TABLE 86 INDIA: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 91
TABLE 87 INDIA: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION) 92
9.4.4 AUSTRALIA 92
9.4.4.1 Favorable R&D tax incentives and cash rebates have driven clinical trial activity in Australia 92
TABLE 88 AUSTRALIA: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020–2027 (USD MILLION) 92
TABLE 89 AUSTRALIA: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 93
TABLE 90 AUSTRALIA: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION) 93
9.4.5 REST OF ASIA PACIFIC 93
TABLE 91 ROAPAC: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020–2027 (USD MILLION) 94
TABLE 92 ROAPAC: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 94
TABLE 93 ROAPAC: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION) 94
9.5 REST OF THE WORLD 95
TABLE 94 ROW: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020–2027 (USD MILLION) 96
TABLE 95 ROW: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 96
TABLE 96 ROW: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION) 96
10 COMPETITIVE LANDSCAPE 97
10.1 OVERVIEW 97
FIGURE 22 KEY GROWTH STRATEGIES ADOPTED BY MARKET PLAYERS FROM 2019–2022 97
10.2 MARKET PLAYER RANKING 98
TABLE 97 GLOBAL CARDIAC SAFETY SERVICES MARKET PLAYER RANKING, 2021 98
10.3 COMPETITIVE LEADERSHIP MAPPING 99
10.3.1 VISIONARY LEADERS 99
10.3.2 DYNAMIC DIFFERENTIATORS 99
10.3.3 INNOVATORS 99
10.3.4 EMERGING COMPANIES 99
FIGURE 23 CARDIAC SAFETY SERVICES MARKET: COMPETITIVE LEADERSHIP MAPPING 100
10.4 COMPETITIVE SITUATION AND TRENDS 101
10.4.1 ACQUISITIONS 101
TABLE 98 ACQUISITIONS, 2019–2022 101
10.4.2 PARTNERSHIPS, ALLIANCES, AND AGREEMENTS 101
TABLE 99 PARTNERSHIPS, ALLIANCES, AND AGREEMENTS, 2019–2022 101
10.4.3 EXPANSIONS 101
TABLE 100 EXPANSIONS, 2019–2022 101
10.4.4 OTHER STRATEGIES 102
TABLE 101 OTHER STRATEGIES, 2019–2022 102
 
11 COMPANY PROFILES 103
(Business overview, Products offered, Recent Developments, MNM view)*
11.1 KEY PLAYERS 103
11.1.1 LABORATORY CORPORATION OF AMERICA HOLDINGS 103
TABLE 102 LABORATORY CORPORATION OF AMERICA HOLDINGS: BUSINESS OVERVIEW 103
FIGURE 24 LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY SNAPSHOT 104
11.1.2 KONINKLIJKE PHILIPS 106
TABLE 103 KONINKLIJKE PHILIPS: BUSINESS OVERVIEW 106
FIGURE 25 KONINKLIJKE PHILIPS: COMPANY SNAPSHOT 107
11.1.3 CLARIO 109
TABLE 104 CLARIO: BUSINESS OVERVIEW 109
11.1.4 BANOOK GROUP 111
TABLE 105 BANOOK GROUP: BUSINESS OVERVIEW 111
11.1.5 IQVIA 112
TABLE 106 IQVIA: BUSINESS OVERVIEW 112
FIGURE 26 IQVIA: COMPANY SNAPSHOT 113
11.1.6 BIOTRIAL 115
TABLE 107 BIOTRIAL: BUSINESS OVERVIEW 115
11.1.7 CERTARA 116
TABLE 108 CERTARA: BUSINESS OVERVIEW 116
FIGURE 27 CERTARA: COMPANY SNAPSHOT 117
11.1.8 CELERION 118
TABLE 109 CELERION: BUSINESS OVERVIEW 118
11.1.9 MEDPACE 119
TABLE 110 MEDPACE: BUSINESS OVERVIEW 119
FIGURE 28 MEDPACE: COMPANY SNAPSHOT 119
11.1.10 NCARDIA 121
TABLE 111 NCARDIA: BUSINESS OVERVIEW 121
11.1.11 RICHMOND PHARMACOLOGY 122
TABLE 112 RICHMOND PHARMACOLOGY: BUSINESS OVERVIEW 122
11.1.12 PHYSIOSTIM 123
TABLE 113 PHYSIOSTIM: BUSINESS OVERVIEW 123
11.2 OTHER PLAYERS 124
11.2.1 SHANGHAI MEDICILON 124
11.2.2 PHARMACEUTICAL PRODUCT DEVELOPMENT LLC. 124
11.2.3 SGS S.A. 125
*Details on Business overview, Products offered, Recent Developments, MNM view might not be captured in case of unlisted companies.
 
12 APPENDIX 126
12.1 DISCUSSION GUIDE 126
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 129
12.3 CUSTOMIZATION OPTIONS 131
12.4 RELATED REPORTS 131
12.5 AUTHOR DETAILS 132